Director?s Overview and Six Essential Characteristics ABSTRACT The City of Hope Comprehensive Cancer Center (COHCCC) brings together 135 Members from 23 Departments in the City of Hope National Medical Center and the Beckman Research Institute of City of Hope. The Center receives $16,688,443 (Direct) in peer-reviewed funding from the NCI, $15,062,557 (Direct) from other peer- reviewed sources, and $31,637,093 from non-peer-reviewed sources, for a total of $63,388,093 (Direct) in overall funding. Through faculty recruitment, reorganization, and significant infrastructure development, the COHCCC has greatly enhanced its ability to accelerate clinical and translational cancer-focused research. Fifty-three new faculty have been recruited during the most recent funding period, including 31 clinical investigators, and 23 basic and population research scientists. The Cancer Center has five Programs: Molecular and Cellular Biology of Cancer (MCBC), Developmental Cancer Therapeutics (DCT), Cancer Immunotherapeutics (CI), Hematologic Malignancies (HM), and Cancer Control and Population Sciences (CCPS). In addition, the COHCCC supports nine Shared Resources: Analytical Cytometry, Analytical Pharmacology, Integrative Genomics & Bioinformatics, Multi-omics Mass Spectrometry & Biomarker Discovery, Pathology Research Services, Small Animal Studies, Drug Discovery & Structural Biology, Biostatistics & Mathematical Oncology, and GMP Manufacturing. Significant infrastructure and other resources have been created to facilitate the translation of discoveries to the rapid development of new cancer treatments, diagnostic tests, and other interventions that will aid people with cancer, as well as individuals at risk for malignancy. Our research is aligned to reduce the incidence of cancer in the unique populations we serve within our Catchment Area, through investigating 1) biologically aggressive cancers that impact diverse populations; 2) viral-related cancers, including hepatocellular carcinoma and HPV and HIV-related malignancies; 3) the impact of pollution on cancer incidence, with a focus on breast and lung cancers; and 4) cancers of aging in Asian- and Latino-Americans. In addition, the COHCCC is committed to developing the next generation of leaders and practitioners in clinical and translational cancer-related research through robust training initiatives that begin at K-12 outreach and continue through junior faculty development. Finally, overall organization of the institution and its administrative capabilities in terms of leadership, programmatic alignment, development, and authority have been augmented so that the Cancer Center will be more responsive to its members and to harness their collective energies and creativity. This application documents that the COHCCC has addressed all of the concerns in the prior review, and that Leadership has built a solid structure for achieving its missions and a stronger more sustainable institution than it has ever been.

Public Health Relevance

The City of Hope Comprehensive Cancer Center provides critical infrastructure and shared resources and fosters collaborations among our basic, population, and clinical investigators to identify new methods for the prevention, diagnosis, treatment, and rehabilitation of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-38
Application #
10059174
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
38
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Weitzel, Jeffrey N; Chao, Elizabeth C; Nehoray, Bita et al. (2018) Somatic TP53 variants frequently confound germ-line testing results. Genet Med 20:809-816
Ghose, Jayeeta; Viola, Domenico; Terrazas, Cesar et al. (2018) Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology 7:e1486948
Aslamy, Arianne; Oh, Eunjin; Olson, Erika M et al. (2018) Doc2b Protects ?-Cells Against Inflammatory Damage and Enhances Function. Diabetes 67:1332-1344
Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707
Röth, Daniel; Chiang, Abby J; Hu, Weidong et al. (2018) Two-carbon folate cycle of commensal Lactobacillus reuteri 6475 gives rise to immunomodulatory ethionine, a source for histone ethylation. FASEB J :fj201801848R
Li, Yi-Jia; Du, Li; Aldana-Masangkay, Grace et al. (2018) Regulation of miR-34b/c-targeted gene expression program by SUMOylation. Nucleic Acids Res 46:7108-7123
Castanotto, Daniela; Zhang, Xiaowei; Alluin, Jessica et al. (2018) A stress-induced response complex (SIRC) shuttles miRNAs, siRNAs, and oligonucleotides to the nucleus. Proc Natl Acad Sci U S A 115:E5756-E5765
Awasthi, Sanjay; Tompkins, Joshua; Singhal, Jyotsana et al. (2018) Rlip depletion prevents spontaneous neoplasia in TP53 null mice. Proc Natl Acad Sci U S A 115:3918-3923
Chaurasiya, Shyambabu; Chen, Nanhai G; Fong, Yuman (2018) Oncolytic viruses and immunity. Curr Opin Immunol 51:83-90
Liu, Stephen V; Groshen, Susan G; Kelly, Karen et al. (2018) A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 82:723-732

Showing the most recent 10 out of 1396 publications